Press Releases

Recently, BOC Sciences, as one of the world’s leading chemical and pharmaceutical vendors, announced the release of a new antibody-drug conjugate technology platform for the scientific community.

Antibody-drug conjugate (ADC) is a new type of highly targeted and highly effective biological drug, which has become a powerful therapeutic agent for tumors and blood diseases in recent years. The mechanism of action of ADC is to bind to the target antigen on the cell surface, and then internalize the target antigen through antigen-mediated endocytosis, transport it to the lysosome, and release it effectively through the proteolytic degradation of the antibody part and the cleavage of the linker load. The principle of ADC development is to link cytotoxic agents with tumor-targeting antibodies to enable them to selectively target cancer cells, leading to the eradication of cancer cells while retaining cells in normal tissues.

Conventional chemotherapy aims to eliminate fast-growing tumor cells, but can damage healthy proliferating cells and cause in undesirable side effects, while ADC aims to improve the therapeutic effect and reduce systemic toxicity. Cytotoxic (anti-cancer) drugs and monoclonal antibodies that recognize specific tumor-associated antigens are connected via disulfide bonds or non-cleavable thioether linkers, which makes the drug combination highly specific. The complex structure of ADC and its high degree of heterogeneity pose a huge challenge to its structural characterization. The ADC coupling strategies provided by BOC Sciences include cysteine conjugation, lysine binding, unnatural amino acids conjugation, carbohydrate Conjugation, and Other Conjugation Approaches.

The design of antibody-drug conjugates (ADC) involves tumor-specific antibodies, linkers and cytotoxic payloads. The payload in ADC is a highly effective cytotoxin that plays a role in key cellular processes. Common toxins used in ADC drugs are highly toxic and have low selectivity. These toxins were often studied as chemical drugs in the past. BOC Sciences provides a series of commonly used ADC cytotoxins, such as Calicheamicin, N-Acetyl-Calicheamicin, 10-Deacetyl-7-xylosyl paclitaxel, Daunorubicin, Actinomycin D, etc. The linker is a bridge between antibodies and cytotoxic drugs. The linker should be sufficiently stable in the circulation so that the payload remains connected to the antibody when it is distributed to tissues. According to different target cells, in vivo and in vitro experiments are used to select the connection method suitable for each drug. For example, antibody-echinomycin conjugates are usually connected by acid-sensitive bonds, while antibody-maytansinol conjugates are usually connected by disulfide bonds or thioether bonds.

BOC Sciences' ADC technology platform provides one-stop comprehensive services for the pharmaceutical industry, including antibody modification and coupling technology, ADC payload development, payload link synthesis, ADC conjugation, ADC characterization And manufacturing. Moreover, BOC Sciences also provides an extensive catalog of linkers, payloads, and payload linker sets. For more information, please visit the website: https://adc.bocsci.com/.

About BOC Sciences

BOC Sciences has been closely involved with drug discovery, chemistry and life science by supplying a comprehensive collection of chemicals to researchers, such as inhibitors, metabolites, impurities and natural compounds. Meanwhile, it also provides a wide range of services through all stages of drug R&D to support the pharmaceutical industry, like custom synthesis of chemicals, isotope labeling, formulation service, antibody drug conjugates, chiral synthesis and resolution.